- Home
- PPCB vs PULM Comparison
PPCB vs PULM Comparison
Compare PPCB & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPCB
- PULM
- Stock Information
- Founded
- PPCB 2007
- PULM 2003
- Country
- PPCB Australia
- PULM United States
- Employees
- PPCB N/A
- PULM N/A
- Industry
- PPCB
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- PPCB
- PULM Health Care
- Exchange
- PPCB Nasdaq
- PULM Nasdaq
- Market Cap
- PPCB 20.4M
- PULM 18.3M
- IPO Year
- PPCB N/A
- PULM N/A
- Fundamental
- Price
- PPCB $1.26
- PULM $4.81
- Analyst Decision
- PPCB
- PULM
- Analyst Count
- PPCB 0
- PULM 0
- Target Price
- PPCB N/A
- PULM N/A
- AVG Volume (30 Days)
- PPCB 337.6K
- PULM 17.3K
- Earning Date
- PPCB 09-30-2025
- PULM 10-16-2025
- Dividend Yield
- PPCB N/A
- PULM N/A
- EPS Growth
- PPCB N/A
- PULM N/A
- EPS
- PPCB N/A
- PULM N/A
- Revenue
- PPCB N/A
- PULM $3,000.00
- Revenue This Year
- PPCB N/A
- PULM N/A
- Revenue Next Year
- PPCB N/A
- PULM $134.88
- P/E Ratio
- PPCB N/A
- PULM N/A
- Revenue Growth
- PPCB N/A
- PULM N/A
- 52 Week Low
- PPCB $1.25
- PULM $2.00
- 52 Week High
- PPCB $145.46
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- PPCB N/A
- PULM 48.87
- Support Level
- PPCB N/A
- PULM $4.55
- Resistance Level
- PPCB N/A
- PULM $4.95
- Average True Range (ATR)
- PPCB 0.00
- PULM 0.18
- MACD
- PPCB 0.00
- PULM 0.01
- Stochastic Oscillator
- PPCB 0.00
- PULM 37.96
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).